Renalytix AI plc (RENX)
London Exchange · UK · prices in GBX · close of 21 Oct 2026
Key indicators
| Last close | GBX 5.350 |
|---|---|
| 52-week range | 1.600 – 10.000 |
| Return, 1 month / 3 months | −14.4% / +94.5% |
| Return, 1 year / 3 years | −38.2% / −88.7% |
| Trend | Uptrend |
| RSI (14) | 44 |
| Volatility (1 year) | 72.3% |
| Worst drawdown (1 year) | -80.5% |
| Average daily value traded | 7.85M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Renalytix is a healthcare diagnostics company that develops artificial intelligence tools for assessing kidney disease. Its main offering is a blood-based test that helps clinicians identify patients with diabetic kidney disease who are at risk of rapid kidney function decline, supporting earlier and more targeted care. The company works with health systems, physicians and payers, and is based in London with operations in the United States.
Renalytix AI plc trades under the code RENX on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Renalytix AI plc (RENX) trades on the London Exchange in UK. It last closed at GBX 5.350 on 21 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,807 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 38.2% and over the last three months it rose 94.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 48.0% | ||
| From 52-week high | -42.2% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 94.5% | ||
| 6-month return | 174.4% | ||
| 12-month return, skipping the last month | -27.7% | ||
| Stability (higher is calmer) | 9 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 72.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -80.5% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 7.85M GBX | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.8% |
|---|---|
| 1 month | −14.4% |
| 3 months | +94.5% |
| 6 months | +174.4% |
| 1 year | −38.2% |
| 3 years | −88.7% |
| 5 years | −99.4% |
Signals
| 50-day / 200-day average | 5.195 / 3.615 |
|---|---|
| Golden / death cross (60 days) | Golden, 24 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.412 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.